Scientists at UC Davis and UC San Francisco have conducted a clinical trial on cats with squamous cell carcinoma, revealing promising results that could extend to human treatments.

Scientists at UC Davis say oral squamous cell carcinoma is one of the most aggressive cancers in cats. Most cats survive only two to three months after diagnosis.

The trial tested a drug targeting a protein called STAT3, which acts like a faulty switch that encourages cancer cells to grow.

During the trial, of the 20 cats treated, seven showed some response to the drug, living an average of 161 days post-treatment. The drug not only blocked STAT3 activity but also increased levels of a protein associated with an immune response to cancer.

Scientists also noted that none of the cats in the trial developed sid

See Full Page